Clinical postoperative recovery after adenotonsillectomy in pediatric age: Role of Pidotimod

Introduction: There are numerous relationships between behaviour and immune system. Is particularly useful to identify the possible role played by a specific molecule to immunostimulant, Pidotimod, on restoring and optimizing physical performance in pediatric patients undergoing adeno-tonsillectomy surgery. Materials and methods: The study was performed on 600 patients, 275 males and 325 females, aged between 5 and 12 years, all subjected to adeno-tonsillectomy surgery. → Group A: 300 patients treated with immunostimulant therapy (Pidotimod) → Group B: 300 untreated patients with no therapy. The treatment of patients in the A group with Pidotimod provided for the administration of the drug, which started soon after hospitalization Parents of all patients provided a specific questionnaire The patient follow-up was divided into three phases: • Phase T0: one week after the adeno-tonsillectomy intervention • Phase T1: three months after the adeno-tonsillectomy intervention • Phase T2: six months after the adeno-tonsillectomy operation. Results: The analysis of the obtained data revealed in its "absolute" evaluation the presence of a difference, somewhat evident, expressed in mean values, between the total score obtained in group A and that in group B. PHASE T0: The analysis of "relative" values, related to each single symptom, identified as the most prevalent phenomena, in descending order of frequency, dysphagia, odinophagia and asthenia PHASE T1: Reduction in the mean value of the mean score for the reference symptoms PHASE T2: Further decrease in the mean score for the reference symptoms in the two different groups Conclusions: The results of the study carried out, highlight the role that immunostimulants, specifically Pidotimod, can be used to optimize healing processes in pediatric patients undergoing adeno-tonsillectomy surgery.